Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histidine ammonia-lyase is a cytosolic enzyme that catalyzes the first step in the catabolism of the amino acid histidine, specifically the nonoxidative deamination of L-histidine to produce ammonia and trans-urocanic acid[1][3][5]. This reaction is essential for histidine degradation in humans and other organisms. HAL is a homotetramer with a unique autocatalytically formed MIO (3,5-dihydro-5-methylidene-4H-imidazol-4-one) cofactor at its active site, which is critical for its catalytic activity[2][4][5]. Mutations in the HAL gene result in histidinemia, an inborn error of metabolism characterized by elevated levels of histidine in blood and urine[1][7]. The enzyme is a member of the aromatic amino acid lyase family and structurally related to phenylalanine ammonia-lyase[3][5][6]. HAL plays a pivotal role in nitrogen metabolism and can serve as a biomarker for metabolic conditions affecting histidine degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histidine ammonia-lyase (HAL).